LL-37 protocol · PepGuide

Check your units. The units in this table assume 1 mg/mL, but the guide's recommended mix makes 2 mg/mL. If you mix it that way, your units will be different. Use the calculator to get the right draw for your vial.

Standard

Weeks 1–4

10–20u (1 mg/mL)

100–200 mcg · 1–3×/week (or daily AM)

SubQ, AM. Start low; injection-site reactions are common (mild inflammatory action).

Off

2–4 weeks

Cycle to limit immune over-stimulation.

Phase	How often	Dose	Units	Notes
Weeks 1–4	1–3×/week (or daily AM)	100–200 mcg	10–20u (1 mg/mL)	SubQ, AM. Start low; injection-site reactions are common (mild inflammatory action).
Off	2–4 weeks	–	–	Cycle to limit immune over-stimulation.

Caution: avoid systemic use if you have an autoimmune or chronic inflammatory condition.

Cycle & timing

Cycle: 4–6 weeks on / 2–4 weeks off.

Timing: Morning SubQ; can be used locally near a wound/infection site under guidance.

Where: SubQ, abdomen, or local to the target area. Rotate.

What to expect

Support for stubborn/biofilm infections and chronic wound healing in research settings. Not a replacement for prescribed antibiotics when those are indicated.

How much to buy

For 6-wk @ 200 mcg × 3/wk:

1–2

× 5mg vials

Men & women

Unisex antimicrobial peptide, same protocol for men and women, no cycle effect. Research-stage; avoid in pregnancy.

Dilution calculator

Set to the guide's typical mix for LL-37. Change anything to see where to draw.

Vial size

BAC water added

Dose you want

Draw to

10u

Volume

0.10 mL

Strength

2 mg/mL

Doses per vial

25

Assumes a U-100 insulin syringe (100 units = 1 mL). Double-check against the compound's page before you draw.

Recommended mixes

Vial	Water	Strength
5 mg	2.5 mL	2 mg/mL

5 mg: 1 unit = 0.02 mg (20 mcg)

Storage

PowderFreeze-dried: -4°F.
MixedReconstituted: 36–46°F, up to 4 weeks.

Don't use if: Active autoimmune or chronic inflammatory disease (systemic use), can worsen it · Pregnancy and lactation · Hypersensitivity to the peptide

Stop if you notice

Flare of an autoimmune/inflammatory condition
Severe or persistent injection-site reaction
Signs of worsening or systemic infection (seek medical care)

Side effects

Injection-site redness/itching/swelling (mild inflammatory property), possible flare of inflammatory conditions.

Drug interactions

Immunosuppressants/biologics: opposing immune effects, coordinate with a clinician; No well-characterized small-molecule interactions

Labs

Inflammatory markers (hsCRP) if used for an inflammatory indication; Monitor any autoimmune condition closely

What these labs mean →

Warnings

Activates dendritic cells, may aggravate psoriasis, lupus, rosacea, IBD; Injection-site inflammation is common; Not a substitute for indicated antibiotics in serious infection; Limited human clinical data for self-administration

Patient education

Powerful antimicrobial, but it stimulates the immune system; not for autoimmune sufferers systemically; Doesn’t replace antibiotics when those are needed for a real infection; Expect some injection-site reaction; start low; Stop for any autoimmune flare

These apply on top of the universal safety rules.

Pairs well with

BPC-157 / TB-500

wound healing

BPC-157 TB-500 (Thymosin Beta-4)

KPV

anti-inflammatory

KPV

GHK-Cu

tissue repair

GHK-Cu

Avoid with

Autoimmune / chronic inflammatory disease

systemic use

Psoriasis, lupus, IBD flares

Pregnancy

Can LL-37 + BPC-157 share a syringe?

Can share a syringe. Both are water-based. Combine them if you dose on the same schedule and site.

What it does

LL-37 is the active fragment of human cathelicidin. It disrupts bacterial membranes and biofilms, neutralizes endotoxin, and modulates immune/wound-healing responses (angiogenesis, re-epithelialization). Because it also activates dendritic cells, it can aggravate autoimmune/inflammatory conditions; a key caution.

References

researchdosing peptidedosages PubMed thepeptidereport

From the guide, page 60.